Imidazoquines as antimalarial and antipneumocystis agents

Vale, N. et al. (2009) Imidazoquines as antimalarial and antipneumocystis agents. Journal of Medicinal Chemistry, 52(23), pp. 7800-7807. (doi: 10.1021/jm900738c) (PMID:19799426) (PMCID:PMC2788672)

Full text not currently available from Enlighten.

Abstract

Peptidomimetic imidazolidin-4-one derivatives of primaquine (imidazoquines) recently displayed in vitro activity against blood schizonts of a chloroquine-resistant strain of Plasmodium falciparum. Preliminary studies with a subset of such imidazoquines showed them to both block transmission of P. berghei malaria from mouse to mosquito and be highly stable toward hydrolysis at physiological conditions. This prompted us to have deeper insight into the activity of imidazoquines against both Plasmodia and Pneumocystis carinii, on which primaquine is also active. Full assessment of the in vivo transmission-blocking activity of imidazoquines, in vitro tissue-schizontocidal activity on P. berghei-infected hepatocytes, and in vitro anti-P. carinii activity is now reported. All compounds were active in these biological assays, with generally lower activity than the parent drug. However, imidazoquines’ stability against both oxidative deamination and proteolytic degradation suggest that they will probably have higher oral bioavailability and lower hematotoxicity than primaquine, which might translate into higher therapeutic indexes.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:De Almeida Marques, Dr Catarina
Authors: Vale, N., Prudêncio, M., Marques, C. A., Collins, M. S., Gut, J., Nogueira, F., Matos, J., Rosenthal, P. J., Cushion, M. T., do Rosário, V. E., Mota, M. M., Moreira, R., and Gomes, P.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Journal of Medicinal Chemistry
Publisher:American Chemical Society
ISSN:0022-2623
ISSN (Online):1520-4804
Published Online:02 October 2009

University Staff: Request a correction | Enlighten Editors: Update this record